• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary: Adjuvant chemotherapy after trimodal therapy for esophageal carcinoma: A bitter pill to swallow.

作者信息

Du Valerie X, Groth Shawn S

机构信息

Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex.

出版信息

JTCVS Open. 2020 Dec 26;5:150-151. doi: 10.1016/j.xjon.2020.12.013. eCollection 2021 Mar.

DOI:10.1016/j.xjon.2020.12.013
PMID:36003186
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9390313/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a889/9390313/28c99fabe9f2/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a889/9390313/28c99fabe9f2/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a889/9390313/28c99fabe9f2/fx1.jpg

相似文献

1
Commentary: Adjuvant chemotherapy after trimodal therapy for esophageal carcinoma: A bitter pill to swallow.评论：食管癌三联疗法后的辅助化疗：难以下咽的苦药。
JTCVS Open. 2020 Dec 26;5:150-151. doi: 10.1016/j.xjon.2020.12.013. eCollection 2021 Mar.
2
Trimodal therapy for muscle-invasive bladder cancer.肌层浸润性膀胱癌的三联疗法。
Expert Rev Anticancer Ther. 2018 Dec;18(12):1219-1229. doi: 10.1080/14737140.2018.1535314. Epub 2018 Oct 17.
3
A bitter pill to swallow: esophageal lesions after PVI may not be what we expected.难以下咽的苦果：肺静脉隔离术后的食管病变可能并非我们所预期的那样。
J Cardiovasc Electrophysiol. 2015 Feb;26(2):127-8. doi: 10.1111/jce.12594. Epub 2015 Jan 14.
4
Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.对于局部晚期食管癌患者，与顺铂/紫杉醇联合治疗相比，新辅助放化疗联合顺铂/5-氟尿嘧啶可提高病理完全缓解率并改善生存率。
Dis Esophagus. 2017 Jul 1;30(7):1-7. doi: 10.1093/dote/dox015.
5
Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).一项评估纳武利尤单抗作为术前多西他赛、顺铂加氟尿嘧啶治疗（PENTAGON 试验）后食管癌患者术后辅助治疗的疗效和安全性的 II 期研究方案。
PLoS One. 2024 Apr 18;19(4):e0299742. doi: 10.1371/journal.pone.0299742. eCollection 2024.
6
Patterns of care amongst older adults diagnosed with locally advanced esophageal cancer: A cohort study.老年局部晚期食管癌患者的治疗模式：一项队列研究。
J Geriatr Oncol. 2022 Nov;13(8):1178-1187. doi: 10.1016/j.jgo.2022.08.009. Epub 2022 Aug 23.
7
Trimodal Therapy in Esophageal Squamous Cell Carcinoma: Role of Adjuvant Therapy Following Neoadjuvant Chemoradiation and Surgery.食管鳞状细胞癌的三联疗法：新辅助放化疗及手术后辅助治疗的作用
Cancers (Basel). 2022 Jul 30;14(15):3721. doi: 10.3390/cancers14153721.
8
Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.新辅助化疗后辅助纳武利尤单抗治疗切除的食管鳞癌患者的短期结局。
Anticancer Res. 2024 Jan;44(1):185-193. doi: 10.21873/anticanres.16801.
9
Bitter pill to swallow: case report of ileal perforation caused by accidental ingestion of a blister pill package.难以下咽的苦果：误吞泡罩药丸包装导致回肠穿孔的病例报告
ANZ J Surg. 2020 Jun;90(6):1164-1165. doi: 10.1111/ans.15448. Epub 2019 Oct 2.
10
Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy.三模态治疗后病理完全缓解的食管鳞癌复发的危险因素。
Anticancer Res. 2020 Aug;40(8):4387-4394. doi: 10.21873/anticanres.14442.

本文引用的文献

1
Residual lymph node disease and mortality following neoadjuvant chemoradiation and curative esophagectomy for distal esophageal adenocarcinoma.新辅助放化疗及根治性食管切除术治疗远端食管腺癌后的残留淋巴结疾病与死亡率
JTCVS Open. 2020 Dec 13;5:135-147. doi: 10.1016/j.xjon.2020.12.001. eCollection 2021 Mar.
2
Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.随机 II 期研究：基于 PET 反应的食管癌放化疗综合治疗：CALGB 80803（Alliance）试验的成熟结果。
J Clin Oncol. 2021 Sep 1;39(25):2803-2815. doi: 10.1200/JCO.20.03611. Epub 2021 Jun 2.
3
Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
新辅助治疗反应对局部晚期食管腺癌的预后价值。
J Thorac Cardiovasc Surg. 2019 Apr;157(4):1682-1693.e1. doi: 10.1016/j.jtcvs.2018.11.131. Epub 2018 Dec 15.
4
Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.新辅助放化疗和食管切除术后辅助化疗在食管癌中的应用。
Ann Surg. 2017 Aug;266(2):297-304. doi: 10.1097/SLA.0000000000001954.